John V. Oyler is the Co-Founder, Chief Executive Officer and Chairman of the Board of Directors of BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, commercial-stage, research-based biotechnology company. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO) and its Health Section Governing Board. Prior to founding BeiGene, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at the Massachusetts Institute of Technology. Mr. Oyler was previously Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. He has also served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology-focused biopharmaceutical company that grew to $1.7 billion in revenues. Mr. Oyler began his career as a management consultant at McKinsey & Company. He received his B.S. from the Massachusetts Institute of Technology and MBA from Stanford University.
GapSummit is the premier, global, intergenerational biotechnology summit that attracts world leaders and the next generation of leaders to substantively discuss pressing challenges facing the bioeconomy and catalyze innovation to address these challenges.
GBR is a not-for-profit that connects biotech think-tanks, industrial leaders and research pioneers to young bio-leaders of tomorrow. GBR is solely led by young passionate and engaged researchers, students and professionals from across the world. GapSummit is GBR’s flagship event to advance its mission of developing and inspiring the next generation of leaders in the global bio-economy.